Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform (PORTRAIT)

Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: an Integrative Multiomics Platform

Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.

Study Overview

• Status: Recruiting
• Conditions: Triple Negative Breast Cancer
• Intervention / Treatment: Diagnostic test: Whole Genome Sequencing; Diagnostic test: RNA-Sequencing; Diagnostic test: Microbiome analysis; Diagnostic test: ctDNA analysis; Diagnostic test: TCR-β repertoire sequencing; Diagnostic test: PBMCs phenotyping; Drug: Pembrolizumab; Drug: Chemotherapy

Detailed Description

The combination of pembrolizumab, an immune checkpoint inhibitor (ICI), with neoadjuvant chemotherapy (NACT) increases pathologic complete response (pCR) and event-free survival (EFS) in patients with early triple negative breast cancer (eTNBC). However, not all patients equally benefit from a treatment that may have relevant adverse events (AEs).

Objectives: (1) To establish predictive biomarkers of response to NACT + ICI in eTNBC by correlating data coming from different layers of omics performed in different tissues, together with imaging, with pCR, EFS, and overall survival (OS). (2) To integrate data generated from (1), and clinical data, and explore multivariate predictive models of response to NACT + ICI.

Methods: Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included. Collected samples and type of analysis: (1) Tumor tissue (baseline and from residual disease after NACT): whole genome sequencing (WGS) and RNA-Seq will be performed (Hartwig sequencing platform and analytical pipeline), tissue immune phenotyping (PD-L1, T and B infiltrating lymphocytes, among others), and microbiome analysis (16S rRNA); (2) Blood (before and during NACT): circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS), T-cell receptor beta (TCR-β) repertoire sequencing and analysis (ImmunoSeq hsTCRβ kit and immunoSEQ), and peripheral blood mononuclear cells (PBMCs) phenotyping; (3) Stools and saliva (before and during NACT): microbiome analysis (16S rRNA); (4) Breast MRI imaging (before and after NACT): radiomics analysis. Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs. The aim is to provide more personalized treatment efficacy and risk for relapse estimates.

Expected outcome: To develop a clinical tool to assist clinicians in the process of treatment decision-making in eTNBC, in order to maximize patient's benefit and quality of life, while minimizing AEs and financial burden to the health system.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Vall d'Hebron Institute of Oncology
    • Contact: Mafalda Oliveira, MD PhD; Phone Number: +34932543450; Email: moliveira@vhio.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included

Description

Inclusion Criteria:

• Histologically documented TNBC (negative human epidermal growth factor receptor 2 [HER2], estrogen receptor [ER], and progesterone receptor [PgR] status)
• Stage 2 - 3 defined by the American Joint Committee of Cancer (AJCC) staging criteria 8th edition for breast cancer as assessed by the investigator based on radiological and/or clinical assessment
• Patient is a candidate to receive NACT with or without ICI as assessed by the investigator
• Patient is ≥ 18 years old at the time of consent to participate in this trial

Exclusion Criteria:

• Metastatic disease on imaging (stage 4)

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cohort A; Pembrolizumab + neoadjuvant chemotherapy	Diagnostic test: Whole Genome Sequencing; Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.; Other Names: WGS; Diagnostic test: RNA-Sequencing; RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).; Diagnostic test: Microbiome analysis; Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.; Diagnostic test: ctDNA analysis; ctDNA analysis will be performed in plasma before and during NACT.; Diagnostic test: TCR-β repertoire sequencing; TCR-β repertoire sequencing will be performed in plasma before and during NACT.; Diagnostic test: PBMCs phenotyping; PBMCs phenotyping will be performed in plasma before and during NACT.; Drug: Pembrolizumab; Pembrolizumab will be given in combination with standard NACT.; Drug: Chemotherapy; Standard NACT will be given.; Other Names: Carboplatin, taxane, anthracycline, cyclophosphamide
Cohort B; Neoadjuvant chemotherapy	Diagnostic test: Whole Genome Sequencing; Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.; Other Names: WGS; Diagnostic test: RNA-Sequencing; RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).; Diagnostic test: Microbiome analysis; Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.; Diagnostic test: ctDNA analysis; ctDNA analysis will be performed in plasma before and during NACT.; Diagnostic test: TCR-β repertoire sequencing; TCR-β repertoire sequencing will be performed in plasma before and during NACT.; Diagnostic test: PBMCs phenotyping; PBMCs phenotyping will be performed in plasma before and during NACT.; Drug: Chemotherapy; Standard NACT will be given.; Other Names: Carboplatin, taxane, anthracycline, cyclophosphamide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathologic complete response (pCR) rate at definitive surgery	The rate (given as a percentage) of patients with a pCR at definitive surgery using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) from the American Joint Committee on Cancer (AJCC) staging criteria	after neoadjuvant treatment and surgery, up to approximately 27-30 weeks
Event-free survival (EFS)	EFS is defined as the time from the start of neoadjuvant treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause	Up to approximately 60 months
Overall survival (OS)	OS is defined as the time from starting neoadjuvant treatment until death due to any cause	Up to approximately 60 months
Identification of biomarkers to predict clinical outcomes (pCR at definitive surgery, EFS, OS).	The clinical data (pCR at definitive surgery, EFS, OS) will be integrated with the results from the multiomics platform and multivariate predictive models of response to neoadjuvant chemotherapy (NACT) + immune checkpoint inhibitor (ICI) will be explored. Precisely, the multiomics platform will analyze: RNA-Sequencing of the initial tumor and residual disease (if present); microbiome analysis of the saliva and feces,; circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS),; Tissue immune phenotyping,; T-cell receptor beta (TCR-β) repertoire sequencing and analysis using ImmunoSeq hsTCRβ kit and immunoSEQ,; Breast MRI imaging (before and after NACT), Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs.	After all data are analyzed, up to approximately 60 months

Collaborators and Investigators

• Sponsor: Vall d'Hebron Institute of Oncology

Study record dates

Study Major Dates

• Study Start (Actual): January 13, 2023
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2029

Study Registration Dates

• First Submitted: May 8, 2023
• First Submitted That Met QC Criteria: June 20, 2023
• First Posted (Actual): June 23, 2023

Study Record Updates

• Last Update Posted (Actual): June 23, 2023
• Last Update Submitted That Met QC Criteria: June 20, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: neoadjuvant chemotherapy; microbiome; triple negative breast cancer; predictive biomarkers; radiomics; immune checkpoint inhibitors; Circulating biomarkers; WGS; multiomics; clinical tool; integrative algorithm; RNA-Sequencing
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Triple Negative Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Cyclophosphamide; Carboplatin; Pembrolizumab
• Other Study ID Numbers: PR(AG)165-2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No